Fast molecular pathogen testing may considerably speed up applicable antibiotic remedy for critically unwell sufferers with suspected pneumonia, in response to findings from the IRISPAT-1 randomised managed feasibility trial.
The examine evaluated whether or not multiplex polymerase chain response (mPCR) testing may enhance antimicrobial decision-making in mechanically ventilated adults with suspected pneumonia. Though molecular panels can quickly establish respiratory pathogens, proof supporting their impression on antimicrobial remedy in important care stays restricted.
Researchers enrolled 40 mechanically ventilated sufferers with suspected pneumonia between July 2024 and October 2025. All members had began new antibiotic remedy inside 24 hours and had been randomly assigned to obtain both commonplace care or testing with the BioFire FilmArray Pneumonia Panel alongside commonplace care.
The first consequence was the time taken for sufferers to obtain applicable antimicrobial remedy.
Applicable Remedy Reached 65 Hours Earlier
Sufferers present process speedy mPCR testing acquired applicable antibiotic remedy significantly ahead of these receiving commonplace care.
Median time to applicable remedy was 7 hours within the mPCR group, in contrast with 72 hours within the standard-care group. This represented a statistically important distinction, with sufferers within the rapid-testing group greater than thrice as prone to attain applicable antimicrobial remedy ahead of controls (HR: 3.3; 95% CI: 1.6–6.6; p=0.001).
Importantly, clinicians demonstrated excessive adherence to the accompanying antibiotic remedy algorithm. Suggestions had been adopted in 18 of the 20 sufferers, akin to an adherence fee of 90%.
The outcomes recommend that combining speedy pathogen identification with a structured antimicrobial remedy algorithm might assist clinicians make focused remedy choices significantly sooner than typical diagnostic approaches.
No Discount in Broad-Spectrum Antibiotic Use
Regardless of the substantial enchancment in time to applicable remedy, speedy testing didn’t considerably have an effect on a number of different antimicrobial or medical outcomes.
Researchers discovered no distinction between teams in the usage of broad-spectrum antibiotics or general period of antibiotic remedy. Equally, ventilator-free days, vasopressor-free days, and 28-day mortality didn’t differ between the 2 remedy methods.
These findings are necessary when decoding the potential medical impression of the intervention. Whereas speedy testing accelerated applicable antimicrobial choice, the small feasibility trial was not in a position to exhibit that this translated into improved affected person outcomes or decreased general antibiotic publicity.
Bigger Trials Wanted to Set up Medical Affect
Fast identification of pathogens could possibly be notably precious in intensive care, the place clinicians usually want to start empirical broad-spectrum antimicrobial remedy earlier than typical microbiological outcomes grow to be accessible.
The IRISPAT-1 findings present preliminary proof that mPCR testing can considerably shorten the time required to achieve applicable remedy when integrated right into a structured antibiotic administration strategy.
Nonetheless, with solely 40 members from a single centre, the outcomes require affirmation in bigger research. Additional analysis will likely be wanted to find out whether or not quicker antimicrobial optimisation can cut back pointless broad-spectrum antibiotic publicity, enhance antimicrobial stewardship, or finally translate into higher medical outcomes for critically unwell sufferers with pneumonia.
Reference
Lai CK et al. Affect of speedy pathogen detection in ICU sufferers with suspected pneumonia on antimicrobial remedy: randomized, managed open-label feasibility trial (IRISPAT-1). BMC Pulm Med. 2026;DOI:10.1186/s12890-026-04596-2.
